Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00203034 · ClinicalTrials.gov registry record · Phase 3

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.

Completed
Registry status
Phase 3
Development phase
472
Enrollment target

NCT00203034: Completed Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.

NCT00203034 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 472 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00203034, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.

COMPLETED
Registry status
Phase 3
Development phase
472 participants
Enrollment target

Study Summary

Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo

Interventions

  • OTHER Placebo
  • DRUG rasagiline mesylate
  • DRUG 1.0 mg rasagiline mesylate

Trial Details

FieldValue
Enrollment Target 472 participants
Start Date 2000-05
Est. Completion 2003-01
Phase Phase 3

What the finished NCT00203034 record still lists

NCT00203034 is an interventional study that assigns participants to a tested intervention. The registered 472 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00203034 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00203034 about?

NCT00203034 is a clinical study titled "Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations". Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo

What is the current status of trial NCT00203034?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 472 participants. The study started on 2000-05. Estimated completion is 2003-01.

What interventions are being tested in trial NCT00203034?

The interventions under investigation include: Placebo (OTHER), rasagiline mesylate (DRUG), 1.0 mg rasagiline mesylate (DRUG).

Who is sponsoring clinical trial NCT00203034?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00203034's enrollment target sits among peer trials

472 811th of 2000 higher than 1,189 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06375083 · 472 participants · Phase 2

    Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression

  • NCT06947187 · 472 participants · NA

    Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere

  • NCT07199517 · 472 participants · NA

    Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit

  • NCT07225881 · 472 participants · NA

    Eatwell Clinical Trial (R01)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00203034, the US trial registry maintained by the National Library of Medicine. NCT00203034 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.